Quest Laboratories Ltd Valuation Shifts: From Very Attractive to Attractive Amid Strong Returns

Valuation Metrics and Recent Changes

As of 4 May 2026, Quest Laboratories Ltd trades at ₹151.65, marking a 4.33% increase from the previous close of ₹145.35. The stock touched a 52-week high of ₹152.60, signalling strong upward momentum. The company’s price-to-earnings (P/E) ratio currently stands at 17.64, a slight moderation from the previous figure of approximately 18.31, which contributed to the valuation grade adjustment from very attractive to attractive. Similarly, the price-to-book value (P/BV) ratio is at 2.76, indicating a moderate premium over book value but remaining reasonable within the sector context.

Other valuation multiples include an enterprise value to EBIT (EV/EBIT) of 15.07 and an EV to EBITDA of 14.47, both reflecting a balanced valuation relative to earnings before interest and taxes and depreciation. The EV to capital employed ratio is 3.18, and EV to sales stands at 2.23, underscoring efficient capital utilisation and sales valuation. Notably, the PEG ratio remains at zero, suggesting either a lack of consensus on growth estimates or a conservative outlook on earnings growth relative to price.

Peer Comparison Highlights

When benchmarked against key peers in the Pharmaceuticals & Biotechnology sector, Quest Laboratories Ltd’s valuation remains attractive. For instance, Bliss GVS Pharma and Kwality Pharma are classified as expensive, with P/E ratios of 26.42 and 28.72 respectively, and EV/EBITDA multiples of 19.72 and 16.3. More expensive peers such as Hester Bios and Jagsonpal Pharma exhibit P/E ratios exceeding 30 and EV/EBITDA multiples above 21, indicating a higher premium for growth or market positioning.

Conversely, Lincoln Pharma and Venus Remedies are rated as fair value, with P/E ratios of 14.72 and 16.99, and EV/EBITDA multiples below 11, suggesting more conservative valuations. Quest Laboratories’ position in the attractive category, with a P/E of 17.64 and EV/EBITDA of 14.47, places it favourably between these extremes, offering a compelling risk-reward balance for investors seeking exposure to the sector without overpaying.

Financial Performance and Returns

Quest Laboratories Ltd’s financial health is underscored by a return on capital employed (ROCE) of 21.12% and a return on equity (ROE) of 15.09%, both indicative of efficient capital management and profitability. These metrics support the valuation attractiveness, as the company generates solid returns relative to its capital base.

In terms of stock performance, Quest Laboratories has significantly outperformed the benchmark Sensex across multiple timeframes. The stock delivered a 26.69% return over the past week compared to a Sensex decline of 0.73%. Over one month, the stock surged 45.26%, dwarfing the Sensex’s 7.46% gain. Year-to-date, Quest Laboratories has appreciated 37.74%, while the Sensex declined by 8.16%. Even on a one-year basis, the stock posted a 38.11% return against the Sensex’s marginal 1.38% loss. This outperformance highlights strong investor confidence and robust operational execution.

Valuation Grade Adjustment: Implications for Investors

The recent downgrade in valuation grade from very attractive to attractive reflects a recalibration rather than a fundamental deterioration. This subtle shift is primarily driven by the slight increase in P/E and P/BV ratios as the stock price approached its 52-week high. While the company’s earnings and capital efficiency remain strong, the market has priced in some of the growth prospects, leading to a more moderate valuation stance.

Investors should note that the current P/E of 17.64 remains below many sector peers, signalling that Quest Laboratories still offers relative value. The company’s micro-cap status may also contribute to valuation volatility, but its strong financial metrics and consistent outperformance versus the Sensex provide a solid foundation for medium-term appreciation.

Sector Context and Market Dynamics

The Pharmaceuticals & Biotechnology sector continues to attract investor interest due to ongoing innovation, regulatory approvals, and increasing healthcare demand. Quest Laboratories, with its robust ROCE and ROE, is well positioned to capitalise on these trends. However, the sector’s valuation spectrum is wide, with some companies trading at very expensive multiples reflecting high growth expectations, while others remain fairly valued or attractive.

In this environment, Quest Laboratories’ attractive valuation grade suggests it is a compelling candidate for investors seeking exposure to quality mid-tier pharmaceutical companies without the premium paid for larger or more speculative peers.

Outlook and Investment Considerations

Given the current valuation and financial metrics, Quest Laboratories Ltd remains a Buy-rated stock with a Mojo Score of 78.0, reflecting strong fundamentals and positive market sentiment. The recent grade change from Strong Buy to Buy on 30 April 2026 signals a more cautious but still optimistic stance, acknowledging the stock’s price appreciation and valuation adjustment.

Investors should weigh the company’s attractive valuation against sector volatility and micro-cap risks. The absence of a dividend yield may be a consideration for income-focused investors, but the company’s reinvestment in growth and solid returns on capital justify the premium valuation.

Overall, Quest Laboratories offers a balanced proposition of growth potential and reasonable valuation, supported by strong operational performance and sector tailwinds. Its consistent outperformance relative to the Sensex over multiple time horizons further reinforces its appeal as a strategic holding within a diversified portfolio.

Conclusion

Quest Laboratories Ltd’s shift in valuation parameters from very attractive to attractive reflects a maturing market view as the stock price approaches its 52-week high. Despite this, the company maintains a favourable position relative to peers, underpinned by robust returns and strong financial discipline. Investors seeking exposure to the Pharmaceuticals & Biotechnology sector would do well to consider Quest Laboratories as a compelling micro-cap opportunity with a solid growth trajectory and reasonable valuation.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →